Belharra Therapeutics Inc.
https://belharratx.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Belharra Therapeutics Inc.
Deals In 2023: Partnerships And Modest M&A
Mid-sized M&A, collaborations, creative financing, and biotech consolidation will feature in 2023. IPOs and follow-ons play bit-parts.
Finance Watch: VC Round Extensions Attractive While Stock Market Wobbles
Private Company Edition: While Coya Therapeutics raised $15.25m in the final initial public offering in the US last year, Apnimed stayed private raising $80m in a series C extension and Metagenomi extended its series B by $100m to total $275m.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Technologies
- Genomics-Proteomics
- Molecular Diversity
-
Drug Discovery Technologies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Belharra Therapeutics Inc.
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice